Results 31 to 40 of about 1,883,437 (383)

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. [PDF]

PLoS Pathogens, 2017
Human cytomegalovirus (HCMV) is an important, ubiquitous pathogen that causes severe clinical disease in immunocompromised individuals, such as organ transplant recipients and infants infected in utero.
Anna Bootz, Astrid Karbach, Johannes Spindler, Barbara Kropff, Nina Reuter, Heinrich Sticht, Thomas H Winkler, William J Britt, Michael Mach   +8 more
doaj   +1 more source

Identification of a conserved neutralizing epitope in Seneca Valley virus VP2 protein: new insight for epitope vaccine designment

Virology Journal, 2022
Background Seneca Valley virus (SVV) is a picornavirus that causes vesicular disease in swine. Clinical characteristics of the disease are similar to common viral diseases such as foot-and-mouth disease virus, porcine vesicular disease virus, and ...
Wei Wen, Xinghua Chen, Qiang Lv, Huanchun Chen, Ping Qian, Xiangmin Li   +5 more
doaj   +1 more source

Characterization of monoclonal and polyclonal antibodies to bovine enteric coronavirus: Establishment of an efficient ELISA for antigen detection in feces [PDF]

, 1989
Monoclonal antibodies to bovine enteric coronavirus (BEC) were produced. Additionally, polyclonal antibodies were made in rabbits and guinea pigs and extracted from the yolk of immunized hens.
Czerny, C. P., Eichhorn, Werner
core   +1 more source

Functional stability of HIV-1 envelope trimer affects accessibility to broadly neutralizing antibodies at its apex [PDF]

, 2017
The trimeric envelope glycoprotein spike (Env) of HIV-1 is the target of vaccine development to elicit broadly neutralizing antibodies (bnAbs). Env trimer instability and heterogeneity in principle make subunit interfaces inconsistent targets for the ...
Gift, Syna Kuriakose, Kim, Arthur S, Leaman, Daniel P, Zhang, Lei, Zwick, Michael B   +4 more
core   +2 more sources

Neutralizing monoclonal antibodies for treatment of COVID-19

Nature reviews. Immunology, 2021
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
P. Taylor, A. Adams, M. Hufford, I. de la Torre, K. Winthrop, R. Gottlieb   +5 more
semanticscholar   +1 more source

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

bioRxiv, 2021
The SARS-CoV-2 Spike glycoprotein mediates virus entry and is a major target for neutralizing antibodies. All current vaccines are based on the ancestral Spike with the goal of generating a protective neutralizing antibody response.
Xiaoying Shen, Haili Tang, C. McDanal, K. Wagh, W. Fischer, J. Theiler, Hyejin Yoon, Dapeng Li, B. Haynes, Kevin O. Sanders, S. Gnanakaran, N. Hengartner, R. Pajon, Gale Smith, F. Dubovsky, G. Glenn, Bette Korber, D. Montefiori   +17 more
semanticscholar   +1 more source

Neutralizing Antibodies against SARS-CoV2

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2023
Coronavirus disease 2019 (COVID-19) is an illness due to a novel coronavirus which is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Though this virus is recently identified in 2019, it is closely related to other coronaviruses namely SARS-
Prachi Athavale, Virendra Athavale, Poonam Suryawanshi, Kishor Khillare, Srikanth Tripathy   +4 more
doaj   +1 more source

bNAber: database of broadly neutralizing HIV antibodies. [PDF]

, 2013
The discovery of broadly neutralizing antibodies (bNAbs) has provided an enormous impetus to the HIV vaccine research and to entire immunology. The bNAber database at http://bNAber.org provides open, user-friendly access to detailed data on the rapidly ...
Burton, Dennis R, Butera, Sal T, Eroshkin, Alexey M, Godzik, Adam, LeBlanc, Andrew, Li, Zhanwen, Post, Kai, Rajput, Akhil, Weekes, Dana   +8 more
core   +4 more sources

Cross-reactive broadly neutralizing antibodies: timing is everything

Frontiers in Immunology, 2012
The recent surge of research into new broadly neutralizing antibodies in HIV-1 infection has recharged the field of HIV-1 vaccinology. In this review we discuss the currently known broadly neutralizing antibodies and focus on factors that may shape these
Zelda eEuler, Hanneke eSchuitemaker, Hanneke eSchuitemaker   +2 more
doaj   +1 more source

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Cellular & Molecular Immunology, 2020
Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotensin-converting enzyme 2 (ACE2) via the receptor-binding
C. Yi, Xiaoyu Sun, Jing Ye, Longfei Ding, Meiqin Liu, Zhuo Yang, Xiao Lu, Yaguang Zhang, Liyan Ma, Wangpeng Gu, Ai-dong Qu, Jianqing Xu, Zhènglì Shí, Z. Ling, Bing Sun   +14 more
semanticscholar   +1 more source